Opinion
Video
Comparing Trials Studying Treatment Intensification In mHSPC
Author(s):
A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, and LATITUDE while highlighting the nuanced differences in adverse effect profiles and tolerability among these agents.
Video Player is loading.
Comparative Analysis With Other mHSPC Trials
Key Themes:
- Comparison between ARANOTE and other intensification trials (ARCHES, TITAN, LATITUDE)
- Differences in patient populations and trial design
- Unique attributes of various androgen receptor pathway inhibitors
Expert Insights:
- Dr Shore compared darolutamide's performance in ARANOTE to other agents: enzalutamide (ARCHES), apalutamide (TITAN), and abiraterone (LATITUDE).
While all agents demonstrated benefit when combined with androgen deprivation therapy, Dr Shore noted important differences in adverse effect profiles, tolerability, and patterns of adoption in clinical practice.
Related Videos
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
BRCA Mutations in mHSPC: Impact on Therapy Selection
Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
Defining and Managing BCG-Unresponsive NMIBC
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
The Incidence of Prostate Cancer and Risk of Progression in Black Men
The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
The Evolvement of Imaging in ccRCC
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Related Content
